Related Experiment Video
Updated: Jun 5, 2026
09:40
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications.
Takatoshi Kasai1, T Douglas Bradley
1Toronto Rehabilitation Institute Sleep Research Laboratory, Toronto, Ontario, Canada.
Journal of the American College of Cardiology
|January 8, 2011
Summary
Obstructive sleep apnea (OSA) is linked to heart failure (HF). Treating OSA may improve heart function and lower blood pressure, but large trials are needed to confirm benefits for HF patients.
Area of Science:
- Cardiology
- Sleep Medicine
- Pulmonology
Background:
- Obstructive sleep apnea (OSA) triggers cardiovascular strain via intermittent hypoxia, oxidative stress, inflammation, and sympathetic overactivation.
- These mechanisms can lead to myocardial dysfunction and contribute to the development and progression of heart failure (HF).
- Observational studies highlight significant associations between OSA and HF, including increased mortality risk in HF patients with moderate to severe OSA.
Purpose of the Study:
- To review the impact of OSA on cardiovascular health and its relationship with heart failure.
- To evaluate the potential benefits of treating OSA on cardiovascular parameters and clinical outcomes in HF patients.
Main Methods:
- Review of epidemiological studies and prospective observational data on OSA and HF.
- Analysis of randomized controlled trials investigating the effects of continuous positive airway pressure (CPAP) treatment for OSA in HF patients.
Main Results:
- Treatment of OSA with CPAP has been shown to reduce sympathetic activity, lower blood pressure, and improve myocardial systolic function in HF patients.
- Evidence suggests a potential for OSA treatment to improve clinical outcomes in individuals with HF.
Conclusions:
- OSA poses significant risks to the cardiovascular system, potentially exacerbating heart failure.
- While current data suggest therapeutic benefits of OSA treatment in HF, large-scale, high-powered randomized trials are essential to definitively establish its role in preventing HF development and reducing morbidity and mortality.
More Related Videos
05:34Auricular Acupuncture as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Sleep Disorders
Published on: August 18, 2023
07:41A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:21Sleep Apnea
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...